Page contentsPage contents Key facts Decision Related medicine information Key facts Invented name GalvusGalvus Active substance vildagliptin Therapeutic area Endocrinology-Gynaecology-Fertility-Metabolism Decision number P/177/2011 PIP number EMEA-000700-PIP02-10 Pharmaceutical form(s) Tablet Condition(s) / indication(s) Treatment of type II diabetes mellitus Route(s) of administration Oral use Contact for public enquiries Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 613241111 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 26/08/2011 Compliance check done No Decision P/177/2011: EMA decision of 26 August 2011 on the granting of a product specific waiver for vildagliptin (Galvus), (EMEA-000700-PIP02-10)Adopted Reference Number: EMA/691227/2011 English (EN) (72.76 KB - PDF)First published: 03/10/2011 Last updated: 03/10/2011 View Related medicine information Galvus Share this page